Exparel
Drug Spine
NDC 65250-266-09
General payments
$1,077,961
Research payments
$0
Through program year 2025, $1,077,961 in general payments and $0 in research payments were reported against Exparel (Spine).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $6,175 | 6 |
| 2024 | General | $26,013 | 12 |
| 2023 | General | $1,030 | 1 |
| 2022 | General | $69,012 | 22 |
| 2021 | General | $117,530 | 66 |
| 2020 | General | $186,396 | 160 |
| 2019 | General | $671,805 | 887 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
1,154 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.